109106 ⎘
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression; Vectors or expression systems specially adapted for eukaryotic hosts for animal cells; Viral vectors Adenoviral vectors
STABILIZATION OF VIRUS-BASED THERAPEUTIC AGENT
#2METHOD FOR RELEASING VIRAL VECTORS
#3HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME
#4CALCIUM CHANNEL 3.2 INHIBITORY PEPTIDES AND USES THEREOF
#5METHOD OF TREATMENT OF HIV INFECTION WITH VACCINE
#6A REPLICATIVE ONCOLYTIC ADENOVIROUS CAPABLE OF INHIBITING TUMOR PROGRESSION AND PROLONGING SURVIVAL TIME IN TUMOR-BEARING INDIVIDUALS AND USE THEREOF
#7THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER
#8METHOD FOR THE PURIFICATION OF RECOMBINANT ADENOVIRUS VECTORS
#9Adenoviral Vectors Comprising Partial Deletions of E3
#10RECOMBINANT ADENOVIRUSES AND USES THEREOF
#11TUMOR-SELECTIVE E1A AND E1B MUTANTS
#12BROWN FAT-SELECTIVE ADIPOKINES
#13Cellular Adjuvants for Viral Infection
#14METHODS FOR TREATING EYE DISEASE
#15Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
#16HEPATITIS B VACCINES AND USES OF THE SAME
#17METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV VECTORS
#18METHOD FOR DELIVERING RNA TO NEURONS TO TREAT HERPES INFECTIONS
#19TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#20GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE
#21GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION
#22Method for Adenovirus Purification
#23ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR
#24IDENTIFYING AND CHARACTERIZING GENOMIC SAFE HARBORS (GSH) IN HUMANS AND MURINE GENOMES, AND VIRAL AND NON-VIRAL VECTOR COMPOSITIONS FOR TARGETED INTEGRATION AT AN IDENTIFIED GSH LOCI
#25HOST CELL LINES AND METHODS FOR IDENTIFYING AND USING SUCH HOST CELL LINES
#26Cellular Adjuvants for Viral Infection
#27METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV VECTORS
#28Adenoviral Vector
#29Cellular Adjuvants for Viral Infection
#30Optimized RPE65 Promoter and Coding Sequences
#31Recombinant adenoviruses and uses thereof
#32TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#33Treatment Of Prion Diseases
#34Methods and Compositions for Modifying a Mutant Dystrophin Gene in a Cell's Genome
#35ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE
#36METHODS AND COMPOSITIONS TO CONFER REGULATION TO GENE THERAPY CARGOES BY HETEROLOGOUS USE OF ALTERNATIVE SPLICING CASSETTES
#37RECOMBINANT AAV1, AAV5, AND AAV6 CAPSID MUTANTS AND USES THEREOF
#38BROWN FAT-SELECTIVE ADIPOKINES
#39EUKARYOTIC CELLS FOR PROTEIN MANUFACTURING AND METHODS OF MAKING THEM
#40SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens
#41Compositions and Methods for Treating Retinal Disorders
#42Targeted neoepitope vectors and methods therefor
#43AAV chimeras
#44AAV CAPSID DESIGNS
#45METHOD FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) BY TARGETING DUX4 GENE
#46Hepatitis C virus immunogenic compositions and methods of use thereof
#47Adenoviral Vectors Comprising Partial Deletions of E3
#48COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
#49GENE THERAPIES FOR LYSOSOMAL DISORDERS
#50Hepatitis B vaccines and uses of the same
#51Tumor-selective E1a and E1b mutants
#52SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
#53Compositions and Methods for Treating Huntington's Disease and Related Disorders
#54Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
#55VACCINE IMMUNOGENS
#56COMPOSITIONS AND METHODS FOR REDUCING NUCLEASE EXPRESSION AND OFF-TARGET ACTIVITY USING A PROMOTER WITH LOW TRANSCRIPTIONAL ACTIVITY
#57IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION
#58METHOD FOR PREPARING MODIFIED VECTOR AND METHOD FOR MODIFYING VECTOR
#59COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS
#60REPLICATION-DEFICIENT AVIAN ADENOVIRAL VECTORS, THEIR DESIGN AND USES
#61METHODS AND COMPOSITIONS FOR VIRAL VECTORED GnRH VACCINES TO CONTROL REPRODUCTION AND BREEDING BEHAVIOR IN MAMMALS
#62METHODS FOR TREATING EYE DISEASE
#63MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY
#64ADENO-ASSOCIATED VIRUS VECTORS BASED GENE THERAPY FOR HEREDITARY ANGIOEDEMA
#65RECOMBINANT AAV FOR TREATMENT OF NEURAL DISEASE
#66TREATMENT OF DISEASES CAUSED BY FRAME SHIFT MUTATIONS
#67Calcium Channel 3.2 Inhibitory Peptides and Uses Thereof
#68AAV3B VARIANTS WITH IMPROVED PRODUCTION YIELD AND LIVER TROPISM
#69VIRAL CAPSID POLYPEPTIDES
#70ADENOVIRAL ASSEMBLY METHOD
#71ANTI-MULLERIAN HORMONE POLYPEPTIDES
#72NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN
#73COMPOSITIONS FOR DRG-SPECIFIC REDUCTION OF TRANSGENE EXPRESSION
#74VECTORS AND GENE THERAPY FOR TREATING CORNELIA DE LANGE SYNDROME
#75Method for delivering RNA to neurons to treat herpes infections
#76Gene Therapy Approaches to Mucolipidosis IV (MLIV)
#77Cellular adjuvants for viral infection
#78TARGETING DELTAFOSB FOR TREATMENT OF DYSKINESIA
#79TARGETED INTEGRATION AT ALPHA-GLOBIN LOCUS IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS
#80AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSTROPHIES
#81ALLOGENEIC CAR-T CELL, PREPARATION THEREFOR, AND APPLICATION THEREOF
#82HUMAN GENE THERAPY METHODS FOR HEMOPHILIA A
#83METHOD FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS
#84AAV CAPSID VARIANTS TARGETING HUMAN GLIOBLASTOMA CELLS
#85Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
#86CA2-IL15 FUSION PROTEINS FOR TUNABLE REGULATION
#87VESTIBULAR SUPPORTING CELL PROMOTERS AND USES THEREOF
#88THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER
#89METHODS AND COMPOSITIONS FOR CELL AND TISSUE REJUVENATION
#90METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS
#91CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORS
#92Fast and Accurate Three-Plasmid Oncolytic Adenovirus Recombinant Packaging System AD5MIXPLUS and Application Thereof
#93Adenoviral vector
#94ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDES
#95MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS
#96ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDES
#97RAAV-GUANYLATE CYCLASE COMPOSITIONS AND METHODS FOR TREATING LEBER'S CONGENITAL AMAUROSIS-1 (LCA1)
#98TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#99SECRETORY PROTEIN
#100Chimpanzee adenoviral vector-based filovirus vaccines
#101EXPRESSION CASSETTES FOR GENE THERAPY VECTORS
#102Modulation of AAV Vector Transgene Expression
#103COMPOSITIONS AND METHODS FOR INTRAVITREAL DELIVERY OF POLYNUCLEOTIDES TO RETINAL CONES
#104Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
#105GENE THERAPIES FOR LYSOSOMAL DISORDERS
#106SYNP162, a promoter for the expression of genes
#107Method for adenovirus purification
#108GENE THERAPY FOR TREATING FAMILIAL HYPERCHOLESTEROLEMIA
#109RECOMBINANT AAV1, AAV5, AND AAV6 CAPSID MUTANTS AND USES THEREOF
#110METHODS AND COMPOSITIONS FOR ASSESSING CRISPR/CAS-MEDIATED DISRUPTION OR EXCISION AND CRISPR/CAS-INDUCED RECOMBINATION WITH AN EXOGENOUS DONOR NUCLEIC ACID IN VIVO
#111Potent and short promoter for expression of heterologous genes
#112CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER
#113Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
#114Homogeneous engineered phage populations
#115FLUID DELIVERY SYSTEMS AND METHODS
#116ANTI-TUMOR COMPOSITION COMPRISING GM-CSF GENE, Flt3L-TRAIL FUSION GENE, shRNA INHIBITING TGF-ß EXPRESSION, AND shRNA INHIBITING HSP EXPRESSION
#117ADENO-ASSOCIATED VIRUS VARIANTS AND METHODS OF USE THEREOF
#118RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF
#119Methods and compositions for dual glycan binding AAV vectors
#120Hepatitis C virus immunogenic compositions and methods of use thereof
#121CA2 compositions and methods for tunable regulation
#122Pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer including CHI3L1 inhibitor as active ingredient
#123Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy
#124RECOMBINANT SINGLE CHAIN IMMUNOGLOBULINS
#125HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME
#126Hepatitis B vaccines and uses of the same
#127Personalized cancer vaccines
#128Gene therapies for lysosomal disorders
#129Adenoviral vectors comprising partial deletions of E3
#130RNA-TARGETING KNOCKDOWN AND REPLACEMENT COMPOSITIONS AND METHODS FOR USE
#131Secretory protein
#132Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene
#133TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#134RETINOL-BINDING PROTEIN 3 (RBP3) AS A PROTECTIVE FACTOR IN NON-DIABETIC RETINAL DEGENERATION
#135AAV chimeras
#136Adeno-associated virus vector
#137Compositions and methods for enhancing functional expression of therapeutic genes in photoreceptors
#138Recombinant adenoviruses and uses thereof
#139Compositions and methods for treating retinal disorders
#140IDENTIFYING AND CHARACTERIZING GENOMIC SAFE HARBORS (GSH) IN HUMANS AND MURINE GENOMES, AND VIRAL AND NON-VIRAL VECTOR COMPOSITIONS FOR TARGETED INTEGRATION AT AN IDENTIFIED GSH LOCI
#141Brown fat-selective adipokines
#142Adeno-associated virus virion for gene transfer to nervous system cells
#143Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules
#144Gene therapies for lysosomal disorders
#145Gene therapies for lysosomal disorders
#146VECTORS CONDITIONALLY EXPRESSING THERAPEUTIC PROTEINS, HOST CELLS COMPRISING THE VECTORS, AND USES THEREOF
#147Gene therapies for lysosomal disorders
#148Optimized RPE65 promoter and coding sequences
#149Treatment of retinitis pigmentosa using engineered meganucleases
#150ADENOVIRAL ASSEMBLY METHOD
#151Adenovirus polynucleotides and polypeptides
#152Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
#153Recombinant simian adenoviral vectors encoding a heterologous fiber protein and uses thereof
#154Cellular adjuvants for viral infection
#155Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
#156Multiple transgene recombinant adenovirus
#157Gene therapies for lysosomal disorders
#158FLUID DELIVERY SYSTEMS AND METHODS
#159Fluid delivery systems and methods
#160Compositions useful in treatment of spinal muscular atrophy
#161Targeted neoepitope vectors and methods therefor
#162METHOD FOR TREATING SCHIZOPHRENIA
#163Recombinant AAV1, AAV5, and AAV6 capsid mutants and uses thereof
#164Method of treating type I diabetes using an AAV vector encoding uracortin 2
#165Adenoviral vectors comprising partial deletions of E3
#166METHODS FOR TREATING EYE DISEASE
#167Methods for treating Parkinson's disease
#168Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens
#169AAV capsid designs
#170Reducing abnormal accumulation of TDP-43 in motor neurons in amyotrophic lateral sclerosis and/or frontotemporal dementia using a construct encoding cyclin F
#171Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
#172Identification of factor that promotes human HSC self-renewal
#173Adenovirus armed with bispecific T cell engager
#174Hepatitis C virus immunogenic compositions and methods of use thereof
#175Eukaryotic cells for protein manufacturing and methods of making them
#176Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
#177Adenoviral vector
#178Methods and compositions for performing continuous directed evolution
#179Secretory protein
#180Compositions and methods for treating Huntington's disease and related disorders
#181Pharmaceutical composition for treating and/or preventing cancer
#182Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
#183RNA GUIDED ERADICATION OF HUMAN JC VIRUS AND OTHER POLYOMAVIRUSES
#184Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
#185SYNTHETIC GUIDE RNA FOR CRISPR/CAS ACTIVATOR SYSTEMS
#186Homogeneous engineered phage populations
#187Strain producing allose from fructose and method for producing allose using same
#188Combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
#189METHOD FOR PREPARING CULTURED CELLS OR TISSUES FOR TRANSPLANTATION
#190Modified interleukin 12 and use thereof in preparing drugs for treating tumours
#191Method using expression of LIN28 for preparing stem cells having excellent renewal ability and therapeutic capacity
#192Gene therapy for treating familial hypercholesterolemia
#193Methods and compositions for dual glycan binding AAV vectors
#194Production of large-sized microdystrophins in an AAV-based vector configuration
#195SYNP162, a promoter for the specific expression of genes in rod photoreceptors
#196Recombinant promoters and vectors for protein expression in liver and use thereof
#197Composition for preventing or treating keloid or hypertrophic scars
#198Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
#199Method for treating schizophrenia
#200Modulation of AAV vector transgene expression
#201Ebola virus disease vaccine taking human replication deficient adenovirus as vector
#202Compositions and Methods for Treatment of Cancer
#203Potent and short promoter for expression of heterologous genes
#204COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
#205Human type 55 replication defective adenovirus vector, method for preparing same and uses thereof
#206Adenovirus polynucleotides and polypeptides
#207Hepatitis C virus immunogenic compositions and methods of use thereof
#208NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS CONTAINING A DESIGNED ANKYRIN REPEAT PROTEIN (DARPIN) OR FRAGMENT THEREOF
#209COMPOSITIONS AND METHODS FOR TISSUE REGENERATION
#210RETINOL-BINDING PROTEIN 3 (RBP3) AS A PROTECTIVE FACTOR IN NON-DIABETIC RETINAL DEGENERATION
#211RAAV-GUANYLATE CYCLASE COMPOSITIONS AND METHODS FOR TREATING LEBER'S CONGENITAL AMAUROSIS-1 (LCA1)
#212Engineered calmodulin for treatment of ryanopathies
#213METHODS AND COMPOSITIONS FOR ENHANCING CARDIAC CONTRACTILITY FOR TREATMENT OF HEART FAILURE
#214Adeno-associated virus variants and methods of use thereof
#215Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
#216RECOMBINANT AAV1, AAV5, AND AAV6 CAPSID MUTANTS AND USES THEREOF
#217Optimized RPE65 promoter and coding sequences
#218Method of treating type I diabetes using an AAV vector encoding uracortin 2
#219Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
#220Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
#221Multitargeting onocolytic adenovirus, methods of use, and methods of making
#222Compositions and methods for the production of scAAV
#223MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES
#224Methods and compositions for enhancing immune responses
#225Compositions and Methods for Treatment of Cancer
#226Methods for reversing multiple resistance in animal cells
#227Adenoviral vectors comprising partial deletions of E3
#228Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
#229Thymidylate kinase fusions and uses thereof
#230Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
#231Adenoviral assembly method
#232Adenoviral vectors for transduction of vascular tissue
#233Fumarylacetoacetate hydrolase (Fah)-deficient pigs and uses thereof
#234Nucleic acid construct and use of the same
#235Adenoviruses and their use
#236Complementing cell lines
#237Adenoviral vectors comprising partial deletions of E3
#238Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof
#239Multiple inducible gene regulation system
#240Adenoviral assembly method
#241Adeno-associated virus vector for gene transfer to nervous system cells
#242rAAV-guanylate cyclase compositions and methods for treating lebers congenital amaurosis-1 (LCA1)
#243Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
#244Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof
#245COMPLEMENTING CELL LINES
#246Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
#247ENGINEERED CD19-SPECIFIC T LYMPHOCYTES THAT COEXPRESS IL-15 AND AN INDUCIBLE CASPASE-9 BASED SUICIDE GENE FOR THE TREATMENT OF B-CELL MALIGNANCIES
#248Methods of inhibiting photoreceptor apoptosis by eliciting the Faim2 antiapoptotic pathway
#249Isolated A-type FHF N-terminal domain peptides and methods of use
#250Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
#251Intracellular viral vector delivery method employing iron ion/viral vector composite
#252Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
#253Thymidylate kinase fusions and uses thereof
#254Multiple inducible gene regulation system
#255Recombinant adenovirus useful for treating malignancy over-expressing proto-oncogene neu/erb B2
#256MODIFIED DENDRITIC CELLS HAVING ENHANCED SURVIVAL AND IMMUNOGENICITY AND RELATED COMPOSITIONS AND METHODS
#257Serotype of adenovirus and uses thereof
#258MULTIPLE INDUCIBLE GENE REGULATION SYSTEM
#259Complementing cell lines
#260Complementing cell lines
#261Serotype of adenovirus and uses thereof
#262TAA/ecdCD40L oncolytic virus